Analyst Ratings for Mirati Therapeutics (MRTX)
MRTX Rating Summary
MRTX Price Target Summary
- Highest: $75.00 (Barclays)
- Lowest: $37.00 (Morgan Stanley)
- Average: $57.57
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$57.57 (+1.6%)
* Over Last 12-Mos
Rating Score: 3.5 / 10
Percentile Rank: 33%
Avg. $ Target:
$57.57 (+1.6%)
* Over Last 12-Mos
Rating Score: 3.5 / 10
Percentile Rank: 33%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/7/2023 | Leerink Partners | Andrew Berens | Downgrade | Market Perform (Outperform) |
58.00 (78.00) |
56.27 (56.65) |
0.68% | Details |
| 11/7/2023 | Stifel | Ben Burnett | Downgrade | Hold (Buy) |
59.00 (83.00) |
56.02 (56.65) |
1.12% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
